Skip to search formSkip to main contentSkip to account menu

desazadesferrithiocin

Known as: (-)-(R)-2-(2,4-dihydroxyphenyl)-4,5-dihydro-4-methyl-4-thiazolecarboxylic acid (4'-hydroxydesazadesferrithiocin) 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

DihydropyridinesThiazoles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Substituent effects on desferrithiocin and desferrithiocin analogue iron-clearing and toxicity profiles.
Desferrithiocin (DFT, 1) is a very efficient iron chelator when given orally. However, it is severely nephrotoxic. Structure… 
2010
2010
A Phase 1B Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of FBS0701, a Novel Oral Iron Chelator for the Treatment of Chronic Iron Overload
Abstract 2057 Background: Iron chelators in current use (parenteral deferoxamine, oral deferasirox and deferiprone) are… 
2007
2007
Impact of the 3,6,9-trioxadecyloxy group on desazadesferrithiocin analogue iron clearance and organ distribution.
The impact of introducing a 3,6,9-trioxadecyloxyl group at various positions of the desazadesferrithiocin (DADFT) aromatic ring… 
2003
2003
Methoxylation of desazadesferrithiocin analogues: enhanced iron clearing efficiency.
The impact of altering the octanol-water partition properties (log P) of analogues of desazadesferrithiocin, (S)-4,5-dihydro-2-(2… 
2003
2003
Iron chelation promoted by desazadesferrithiocin analogs: An enantioselective barrier.
For patients who require lifelong blood transfusions, there is no efficient means, unless chelation therapy is employed, for… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)